Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 4Prostatic Neoplasms 2Bile Duct Neoplasms 2Vulvar Neoplasms 1Sarcoma 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Hereditary Sensory and Autonomic Neuropathies 1Gallbladder Neoplasms 1Disease Progression 1Clear-cell metastatic renal cell carcinoma 1Cholangiocarcinoma 1Carcinoma, Neuroendocrine 1Breast Neoplasms 1

Interventions

Nivolumab 3capivasertib 2Gemcitabine 2Cisplatin 2tivozanib 1regorafenib 1niraparib 1neratinib 1lutetium Lu 177 dotatate 1fludarabine phosphate 1fludarabine 1encorafenib 1durvalumab 1copanlisib 1cemiplimab 1axicabtagene ciloleucel 1avasopasem manganese 1Valproic Acid 1Thioctic Acid 1Taxes 1Receptors, Interleukin-6 1Radiosurgery 1RNA-Seq 1Pemetrexed 1Paclitaxel 1Oxaliplatin 1Multiparametric Magnetic Resonance Imaging 1Leucovorin 1Lenalidomide 1Interleukin 1 Receptor Antagonist Protein 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Disease Progression × tivozanib × 1 year × Clear all
NCT04987203 2026-05-08

Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

AVEO Pharmaceuticals, Inc.

Phase 3 Completed
343 enrolled
Genitourinary

Carcinoma, Renal Cell, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡